Editorial scope & study tiers
About Order GHK-Cu and the published GHK-Cu evidence
An examination of fifty years of copper-peptide publications, separating what was tested in humans from what stayed on a laboratory bench.
Human GHK-Cu trials and animal research studies
Order GHK-Cu is a non-commercial reading guide that stocks nothing, sells nothing, dispenses nothing, and takes no orders. I question GHK-Cu summaries that treat cell-dish gene percentages and rodent injections as equivalent to human clinical trials.
Across online copper-peptide summaries, numbers from completely different biological systems frequently get blended together — a 70% collagen figure from a skin regeneration review (Pickart et al. 2015) sitting right next to a 31.2% gene-shift figure from a Connectivity Map cell-culture analysis (Pickart and Margolina 2018) and milligram-per-kilogram injections in aged mice (Dou et al. 2020).
How GHK-Cu studies and safety data are compared
Loren Pickart isolated GHK in 1973 and co-authored many of the broad synthesis reviews (2008 and 2012 and 2015 and 2018). Where other research teams tested the peptide — such as the 2006 laser resurfacing trial in 13 patients, the 2012 Genome Medicine lung fibroblast study, or the 2016 six-month ALAVAX scalp study in 45 men — small sample sizes, combination-product formulas, and mixed objective endpoints temper the sweeping claims common on research-use forums.
Nothing on Order GHK-Cu is medical advice or a dosing or treatment instruction. Questions about skin conditions, hair loss, or medications require a qualified medical professional. If you spot a citation error on any page, please use the contact page to send the paper details.